Novartis AG ADR (NVS)vsTransMedics Group Inc (TMDX)
NVS
Novartis AG ADR
$160.32
-0.04%
HEALTHCARE · Cap: $303.67B
TMDX
TransMedics Group Inc
$92.00
-0.01%
HEALTHCARE · Cap: $3.16B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 7783% more annual revenue ($57.36B vs $727.65M). TMDX leads profitability with a 19.9% profit margin vs 17.5%. TMDX appears more attractively valued with a PEG of 0.80. TMDX earns a higher WallStSmart Score of 62/100 (C+).
NVS
Hold48
out of 100
Grade: D+
TMDX
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.8%
Fair Value
$95.76
Current Price
$160.32
$64.56 premium
Margin of Safety
+56.3%
Fair Value
$304.76
Current Price
$92.00
$212.76 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 34.3%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Every $100 of equity generates 35 in profit
Revenue surging 41.1% year-over-year
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
Distress zone — elevated risk
Elevated debt levels
Earnings declined 29.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : TMDX
The strongest argument for TMDX centers on Return on Equity, Revenue Growth, PEG Ratio. Profitability is solid with margins at 19.9% and operating margin at 13.9%. Revenue growth of 41.1% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : TMDX
The primary concerns for TMDX are Altman Z-Score, Debt/Equity, EPS Growth. Debt-to-equity of 1.67 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a value stock while TMDX is a growth play — different risk/reward profiles.
TMDX carries more volatility with a beta of 2.10 — expect wider price swings.
TMDX is growing revenue faster at 41.1% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Bottom Line
TMDX scores higher overall (62/100 vs 48/100), backed by strong 19.9% margins and 41.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →TransMedics Group Inc
HEALTHCARE · MEDICAL DEVICES · USA
TransMedics Group, Inc., a commercial-stage medical technology company, is dedicated to transforming organ transplant therapy for patients with end-stage organ failure in the United States and internationally. The company is headquartered in Andover, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?